Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9758582
SERIAL NO

15145135

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

First Claim

See full text

Other Claims data not available

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOCON LIMITEDKARNATAKA BANGALORE 560 100

International Classification(s)

loading....
  • 2016 Application Filing Year
  • A61K Class
  • 19101 Applications Filed
  • 13019 Patents Issued To-Date
  • 68.16 % Issued To-Date
Click to zoom InYear of Issuance% of Matters IssuedCumulative IssuancesYearly Issuances20162017201820192020202120222023202420250255075100

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Govindappa, Nagaraj Karnataka, IN 18 82
Sastry, Kedarnath Karnataka, IN 10 58
Soares, Maria Melina Karnatake, IN 12 66

Cited Art Landscape

Load Citation

Patent Citation Ranking

  • 4 Citation Count
  • A61K Class
  • 45.09 % this patent is cited more than
  • 8 Age
Citation count rangeNumber of patents cited in rangeNumber of patents cited in various citation count ranges763281956782001332911183139501 - 1011 - 2021 - 3031 - 4041 - 5051 - 6061 - 7071 - 8081 - 9091 - 100100 +050010001500200025003000350040004500500055006000650070007500800085009000

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 12, 2029